Vaccine manufacturers, in particular, are preparing to rebuff a wave of disinformation about the safety and efficacy of vaccines, given that the expected nominee for US Health and Human Services secretary has espoused anti-vaccine rhetoric in the past.
Vaccine Manufacturers To Fight Disinformation With Transparency
At the J.P. Morgan Healthcare Conference, GSK, Sanofi and Pfizer said they are prepared to address questions about vaccines under a new US administration, while former FDA Commissioner Scott Gottlieb warned of threats to public safety.

More from Vaccines
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."
Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.
The disruption of CDC’s Advisory Committee on Immunization Practices meeting schedule adds fuel to concerns about potential alterations of the vaccine schedule raised by former FDA Commissioner Scott Gottlieb.
More from Pink Sheet
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.